SCHEMBL3916840

SCHEMBL3916840

CCN(C1(C(=O)NO)CCC1)S(=O)(=O)c1ccc(Oc2ccc(S(C)(=O)=O)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 14/20 0.63
▸ MMP13 P45452 15/20 0.47
▸ MMP9 P14780 8/20 0.47
▸ MMP2 P08253 6/20 0.47
▸ MMP14 P50281 6/20 0.47
▸ ADAM17 P78536 5/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ BMP1 P13497 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MMP3 P08254 3/20 0.40
▸ MMP8 P22894 3/20 0.40
▸ ABCB11 O95342 1/20 0.39
▸ MMP7 P09237 1/20 0.39
▸ MMP10 P09238 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3915124 0.98 MMP1 (0.60) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3920825 0.97 MMP1 (0.59) MMP1MMP13MMP9MMP2MMP14
SCHEMBL13899017 0.90 MMP1 (0.52) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3914343 0.88 MMP1 (0.60) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3915716 0.88 MMP1 (0.57) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3922892 0.86 MMP1 (0.61) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3914710 0.86 MMP1 (0.78) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3913267 0.86 MMP1 (0.55) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3923541 0.86 MMP1 (0.60) MMP1MMP13MMP9MMP2MMP14
SCHEMBL3913080 0.85 MMP1 (0.59) MMP1MMP13MMP9MMP2MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504537-B2 Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-03-17 — — US disclosed
US-7504537-B2 Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-03-17 — — US disclosed
US-7504537-B2 Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-03-17 — — US disclosed
US-20050282905-A1 Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282905-A1 Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient MMP13, MMP3, MMP2 MMP1 11/4885MMP13 1/4885MMP9 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback